Proteasomes function as the cellular “garbage disposals” responsible for degrading and recycling damaged or unneeded proteins. These molecular complexes are vital for maintaining cellular homeostasis, especially in rapidly dividing cells such as cancer cells that generate large volumes of defective or misfolded proteins. Inhibition of the proteasome pathway leads to an accumulation of protein waste, triggering cellular stress and, ultimately, apoptosis in susceptible cancer types like multiple myeloma. However, AML’s intrinsic resistance to proteasome inhibitors has long puzzled researchers and clinicians alike. The UC San Diego team’s latest research elucidates this resistance by revealing AML’s ability to activate compensatory stress-response mechanisms that bypass the blockade of proteasome activity.

Central to this resilience are two alternative degradation pathways AML cells employ: one governed by the heat shock factor 1 (HSF1) gene and the other autophagy, a self-digestive process that cells use to recycle damaged organelles and proteins. Unlike multiple myeloma cells which succumb to proteasome inhibition, AML cells deftly reroute their intracellular traffic to these secondary systems, effectively circumventing the therapeutic “roadblock.” Through this molecular detour, AML cells continue to clear toxic protein aggregates and sustain their pathogenic proliferation. Consequently, monotherapy with proteasome inhibitors fails to produce clinically meaningful responses in most AML patients.

Lead investigator Robert Signer, Ph.D., explains this biological contingency with a vivid analogy: AML cells encountering proteasome inhibition are akin to drivers rerouting around a highway construction zone via alternative exits, whereas multiple myeloma cells become trapped in gridlock. This “off-ramp” detour mechanism allows AML to maintain proteostasis under proteasome stress, a discovery that shaped the team’s approach to overcoming therapeutic resistance. By designing combinatorial interventions that simultaneously target the proteasome and these backup pathways, researchers aimed to cut off AML’s escape routes.

To this end, the study evaluated the effect of co-administering proteasome inhibitors with Lys05, a potent autophagy inhibitor. Lys05 functions by disrupting the lysosomal degradation pathway, thus impeding cellular autophagy. Experimental data derived from cultured AML patient cells demonstrated a significant reduction in cancer cell viability and colony formation, affirming that dual inhibition effectively overwhelms AML’s protein clearance systems. Moreover, in preclinical mouse models, this therapeutic strategy not only diminished disease burden but also substantially extended survival without inducing significant toxicity, underscoring its potential clinical relevance.

Kentson Lam, M.D., Ph.D., the study’s first author, emphasizes the critical advantage of this approach: it is largely mutation-agnostic. Given the broad spectrum of genetic alterations driving AML, personalized therapies targeting specific mutations benefit only subsets of patients. The dual pathway targeting demonstrated efficacy in a wide array of AML cell lines and patient-derived samples regardless of their mutational landscape, offering a more universally applicable treatment paradigm. This breakthrough moves the field closer to therapies capable of overcoming one of AML’s most vexing challenges—the extreme heterogeneity and adaptability of tumor cells.

The researchers underscore the translational potential of these findings as they pursue further identification of compounds capable of disabling AML’s multifaceted survival pathways. This includes exploring drugs that suppress HSF1-regulated stress responses, which, when combined with proteasome inhibitors and autophagy blockers, could comprehensively cripple AML’s proteostatic defenses. Such combinations have the potential to enter early-phase clinical testing, laying the groundwork for novel, more effective AML treatment regimens.

Interestingly, the team leveraged their extensive expertise in stem cell biology to inform their therapeutic strategy. Unlike multiple myeloma cells, AML cells originate from hematopoietic stem cells, imparting unique physiological traits and resilience mechanisms. Understanding the molecular circuitry that governs stem cell proteostasis illuminated the rationale for targeting multiple recycling pathways simultaneously. This cross-disciplinary insight exemplifies how fundamental biology can guide innovative cancer therapy development.

This work also challenges the conventional focus on genetic mutations as the primary targets for AML treatment, by suggesting that cancer cell metabolism and protein homeostasis represent vulnerable aspects that can be therapeutically exploited. Targeting the cell’s stress response and degradation systems disrupts the cancer cells’ ability to manage proteotoxic stress, tipping the balance towards cell death. This paradigm shift could inspire similar approaches across other malignancies marked by therapeutic resistance.

Ultimately, the significance of this research lies in its promise to expand treatment options for AML patients, many of whom currently face limited and toxic therapies. By illuminating the mechanisms of AML cell survival under proteasome inhibition and pioneering combination strategies to overcome those defenses, this study offers new hope for improving patient outcomes in a disease notorious for its lethality. The research community and medical practitioners alike eagerly anticipate further validation of these findings in clinical trials, which could herald a new era of mutation-agnostic, pathway-targeted therapies for AML.

The fight against AML continues to underscore the complexity of cancer biology but also highlights how unraveling a tumor’s survival tactics at a molecular level can yield transformative therapeutic insights. As Signer remarks, the ultimate objective is to translate scientific discovery into treatments that enhance patients’ lives—a goal that this breakthrough brings tantalizingly within reach.

Subject of Research: Acute myeloid leukemia (AML), proteasome inhibitors, autophagy mechanisms, cancer therapy resistance.

Article Title: Not specified.

News Publication Date: October 20, 2025.

References: Published in Blood, October 20, 2025.

Keywords: Myeloid leukemia, multiple myeloma, stem cells, autophagy, protease inhibitors.

Proteasome inhibitors have long been a staple in the treatment of multiple myeloma, but their specific mechanisms had remained somewhat of a mystery. In this breakthrough research, the City of Hope team used advanced scientific techniques to dissect the intricate interactions between reovirus, cancer cells, and the immune system. One of their significant findings was the ability of proteasome inhibitors to enhance viral replication within immune cells, specifically monocytes. This increase in replication was crucial as it improved the delivery of the virus into the cancerous cells, setting off a chain reaction contributing to the destruction of tumors.

Another important aspect discussed by the researchers was the role of the NF-κB signaling pathway within the immune system when proteasome inhibitors are present. They noted that the inhibitors weakened this pathway, which had implications for how monocytes handle viral infections. The researchers discovered that as the monocytes activated their immune response under the influence of proteasome inhibitors, they turned their defenses against the multiple myeloma cells, attacking and killing them more efficiently than before. This dual action of the therapy presents a multifaceted approach to addressing cancer treatment.

In a clinical setting, the researchers conducted a small-scale trial involving 13 multiple myeloma patients whose cancer had resisted previous treatments. The results were promising; approximately 70% of the participants demonstrated a positive response to the combined therapy. Notably, this included active viral replication within their cancer cells and heightened T cell activity, which is instrumental in orchestrating an effective immune response against cancers. These findings suggest that combining viral therapies with established cancer drugs can be a game changer in the fight against resistant forms of myeloma.

Furthermore, the research highlighted the ongoing debate about the utility of circulating tumor DNA (ctDNA) testing in colorectal cancer patients post-surgery. While ctDNA testing has been adopted widely to monitor disease recurrence by detecting traces of tumor DNA in the bloodstream, recent analysis indicates that its integration into standard post-operative surveillance does not significantly enhance patient outcomes. In a retrospective study encompassing 184 patients at City of Hope who underwent colorectal cancer surgeries, the researchers found that only a few individuals benefitted from this additional layer of monitoring.

The results were telling; of the patients who showed early signs of recurrence through ctDNA testing before conventional imaging, only a minuscule fraction went on to receive curative interventions. In contrast, a higher proportion of patients whose recurrences were identified via traditional imaging methods received effective treatments that led to disease-free statuses, illuminating potential limitations in the effectiveness of serial ctDNA monitoring as part of follow-up care.

In surgical practices, the advent of remote patient monitoring (RPM) has gained traction, particularly following the COVID-19 pandemic that forced many healthcare systems to adopt digital solutions. Experts from City of Hope emphasize that RPM can greatly enhance the quality of care delivered to surgical patients by facilitating continuous health monitoring through sensors, wearables, and mobile technology. The benefits of RPM extend beyond mere convenience; it enhances the triaging process, ensuring that patients receive timely in-person follow-ups when necessary.

The guide outlined by leading surgeons at City of Hope elaborates on the potential of RPM to improve post-operative recovery outcomes while reducing rates of hospital readmissions. Designed to be economical and accessible, the guide suggests that RPM systems can utilize affordable multisensors to track various health metrics post-surgery, providing valuable data that can guide clinical decision-making for patient management and follow-up care.

The focus on preventative screening in high-risk populations remains paramount, particularly within the context of breast cancer. In examining compliance rates for enhanced MRI screenings among women genetically predisposed to breast cancer, researchers found that those identified with high-risk genetic variants exhibited significantly improved screening rates compared to their moderate-risk counterparts. This reinforces the critical role that genetic counseling and testing play in ensuring that at-risk populations receive the necessary preventative measures against cancer.

Expanding the conversation around treatment efficacy for relapsed cases, the exploration of innovative therapies is gaining momentum. The trials surrounding obecabtagene autoleucel (obe-cel), a novel CAR T cell therapy for adult patients with B cell acute lymphoblastic leukemia (B-ALL), reveal compelling results. With a notable remission rate observed in participants of a phase 1b-2 trial, the efficacy of this therapy represents a noteworthy advancement in managing one of the more difficult diseases to treat effectively.

The safety profile recorded in this trial, which spanned multiple countries, further suggests that innovations such as CAR T therapies can be optimized to provide durable efficacy without eliciting severe side effects typically seen in traditional treatments. These findings present an optimistic outlook for patients who have exhausted existing treatment options and represent a significant advancement in personalized cancer therapy approaches.

As research progresses at institutions like City of Hope, the landscape of cancer treatment is continuously evolving, with each study paving the way for new possibilities. The integration of comprehensive treatment modalities that combine existing drugs with novel therapies, coupled with advances in monitoring and preventative strategies, underscores a holistic approach to tackling cancer. The ultimate goal remains steadfast: to enhance treatment outcomes, improve survival rates, and make significant strides in combating this pervasive disease.

Subject of Research: Enhancing Viral Immunotherapy for Multiple Myeloma and Evaluating ctDNA Testing in Colorectal Cancer
Article Title: Advancements in Cancer Treatment: Viral Immunotherapy, ctDNA Testing, Remote Monitoring, and Genetic Screening
News Publication Date: October 2023
Web References: City of Hope
References: Available within the original publication.
Image Credits: City of Hope Media Library

Keywords: Viral immunotherapy, multiple myeloma, circulating tumor DNA, colorectal cancer, remote patient monitoring, breast cancer screening, CAR T therapy, B cell acute lymphoblastic leukemia.